Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.34 |
| ▸ | MDM4 | O15151 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.34 |
| ▸ | TACR2 | P21452 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | NAAA | Q02083 | 2/20 | 0.33 |
| ▸ | ANPEP | P15144 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15087262 | 1.00 | L3MBTL1 (0.37) | L3MBTL1POLBTP53MDM2MDM4 | |
| SCHEMBL15087304 | 1.00 | L3MBTL1 (0.37) | L3MBTL1POLBTP53MDM2MDM4 | |
| SCHEMBL15087260 | 1.00 | L3MBTL1 (0.37) | L3MBTL1POLBTP53MDM2MDM4 | |
| SCHEMBL15087226 | 0.89 | TACR2 (0.37) | L3MBTL1POLBTACR2LMNAKMT2A | |
| SCHEMBL15087222 | 0.89 | TACR2 (0.37) | L3MBTL1POLBTACR2LMNAKMT2A | |
| SCHEMBL15087223 | 0.89 | TACR2 (0.37) | L3MBTL1POLBTACR2LMNAKMT2A | |
| SCHEMBL15087285 | 0.89 | TACR2 (0.37) | L3MBTL1POLBTACR2LMNAKMT2A | |
| SCHEMBL15087225 | 0.89 | TACR2 (0.37) | L3MBTL1POLBTACR2LMNAKMT2A | |
| SCHEMBL15087268 | 0.87 | CTSL (0.38) | L3MBTL1POLBALDH1A1NAAA | |
| SCHEMBL15087266 | 0.87 | CTSL (0.38) | L3MBTL1POLBALDH1A1NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9175044-B2 | Derivatives of glyco-CF2-serine and glyco-CF2-threonine | TFCHEM (FR) | 2015-11-03 | — | — | US | disclosed |
| US-20130171180-A1 | DERIVATIVES OF GLYCO-CF2-SERINE AND GLYCO-CF2-THREONINE | TFCHEM (FR) | 2013-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130171180-A1 | DERIVATIVES OF GLYCO-CF2-SERINE AND GLYCO-CF2-THREONINE | PTMS, SLC5A2, INF2 | L3MBTL1 3911/4885POLB 4428/4885TP53 3243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.